艾博生物获得7亿美元C轮投资;拓璞科技完成5亿元C轮融资;滴普科技获得1亿美元B轮融资

2022-11-21
837
778

Author:Aibo Biotech obtained a round C investment of 700 million US dollars; Tuopu Technology completed round C financing of 500 million yuan; Dipper Technology obtained 100 million USD round B financing
Source: iResearch

Introduction:Aibo Biotech obtained a round C investment of 700 million US dollars; Tuopu Technology completed round C financing of 500 million yuan; Dipper Technology obtained 100 million USD round B financing

[Investment and Financing Newseight20 - 22]AIBO Bio is a new nucleic acid drug R&D company, committed to the research and development of new drugs based on nucleic acids (siRNA, mRNA, DNA), and the target diseases include cancer and infectious diseases.companyThe total amount announced to be completed a few days ago exceeded 7YimeiRound C of RMBfinancing

Tuopu Technology is a high-end manufacturing technology enterprise committed to providing intelligent manufacturing equipment and process solutions for aerospace enterprises. The products are mainly used in the field of aerospace vehicle production, including five axis linkage CNC machine tools, aerospace department/assembly intelligent equipment and intelligent production lines. Recently announced the completion of 500 million yuan round C financing.

Dipp Technology is a full scene data intelligent technology company. Based on data intelligence technology, the company has penetrated outstanding digital capabilities into various industry scenarios, and supported enterprises to achieve digital transformation breakthrough from strategy to technology implementation. Recently, it was announced to complete the round B financing of 100 million US dollars.

China Overseas Information Investment and Financing News | Albo Bio has obtained a round C investment of 700 million US dollars; Tuopu Technology completed round C financing of 500 million yuan; Dipper Technology obtained 100 million USD round B financing

(This document isIrinetFor the reprint of exclusive original manuscript, please indicate the source)
The content of the article is created by the author, and the author is responsible for the authenticity, accuracy and legality of the content. Overseadia advocates respecting and protecting intellectual property rights. Without the permission of the author and/or this website, the content of this website may not be copied, reproduced, or used in other ways. If you find that there are copyright issues in the articles on this site, please contact chuhaiyi@baidu.com, and we will verify and deal with them in time. Source of the article: iResearch, this article is the author's independent point of view, and does not represent the position of overseadia.